Anti-SARS-CoV-2 spike protein single-domain antibody.
Catalog no.:
Q103c
Clone name:
QCV-1F6
Product summary.
Product:
Single-domain antibody directed against SARS-CoV-2 spike protein
Target:
SARS-CoV-2 spike protein
Target description:
The disease COVID-19 is caused by the virus SARS-CoV-2 and is responsible for the global pandemic starting in 2020. SARS-CoV-2 is a spherical-shaped positive-strand RNA virus. The SARS-CoV-2 spike protein (S protein) is a homotrimeric transmembrane glycoprotein that is one of the major protein complexes on the virus and which plays an important role in infection into host cells. Each spike protein monomer is a 140 kDa protein with an N-terminal S1 domain, a membrane-proximal S2 domain, a transmembrane domain, and a C-terminal domain. Via the receptor binding domain (RBD) within the S1 domain, the spike proteins bind to Angiotensin-Converting Enzyme 2 (ACE2) receptors on host cells, which is then followed by fusion of the virus with the membrane. By interfering with the interaction of the RBD with ACE2, infection can be blocked.3 Therefore, S1 and in particular RBD is an interesting therapeutic target for COVID-19.
Source:
Recombinant monoclonal single-domain antibody (Lama glama), purified from S. cerevisiae using affinity chromatography. Immunization with and phage-display selection on recombinant protein using total elution.
Product details.
Specificity:
SARS-CoV-2 spike protein domain S1.
Formulation:
0.2 µm filtered solution in PBS. The products are equipped with a C-terminal C-Direct tag with an unpaired cysteine for directional conjugation.
Mol. Weight:
14.7 kDa
Ext. Coeff. (ε):
18575 M-1cm-1
A280 at 1g/L:
1.3
Storage:
Shipped on blue ice. Store at 4˚C or -20˚C (aliquots). Addition of 0.02% sodium azide is optional.
